A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants

Mostrar otras versiones (1)

Several vaccines have been introduced to combat the coronavirus infectious disease‐2019 (COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Current SARS‐CoV‐2 vaccines include mRNA‐containing lipid nanoparticles or adenoviral vectors that encode the SARS‐CoV‐...

全面介紹

書目詳細資料
Autores principales: Jiang, Linglei, Driedonks, Tom A.P., Jong, Wouter S.P., Dhakal, Santosh, Bart van den Berg van Saparoea, H., Sitaras, Ioannis, Zhou, Ruifeng, Caputo, Christopher, Littlefield, Kirsten, Lowman, Maggie, Chen, Mengfei, Lima, Gabriela, Gololobova, Olesia, Smith, Barbara, Mahairaki, Vasiliki, Riley Richardson, M., Mulka, Kathleen R., Lane, Andrew P., Klein, Sabra L., Pekosz, Andrew, Brayton, Cory, Mankowski, Joseph L., Luirink, Joen, Villano, Jason S., Witwer, Kenneth W.
格式: Online Artículo Texto
語言:English
出版: John Wiley and Sons Inc. 2022
主題:
Research Articles
在線閱讀:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920961/
https://www.ncbi.nlm.nih.gov/pubmed/35289114
http://dx.doi.org/10.1002/jev2.12192

因特網

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920961/
https://www.ncbi.nlm.nih.gov/pubmed/35289114
http://dx.doi.org/10.1002/jev2.12192

相似書籍